Mebeverine
Is It Right for You?
A complete guide to Mebeverine — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Mebeverine?
Mebeverine is a musculotropic antispasmodic medication used in the symptomatic management of irritable bowel syndrome (IBS) and other functional bowel disorders. It belongs to a class of drugs that act directly on the smooth muscle of the gastrointestinal tract to relieve painful muscle spasm, without significantly affecting normal bowel motility or producing the systemic side effects associated with anticholinergic antispasmodics.
Mebeverine is available in the UK as 135 mg immediate-release tablets (taken three times daily before meals) and as 200 mg modified-release capsules (taken twice daily before meals). It is also available in combination with ispaghula husk as Fybogel Mebeverine — a single preparation that combines antispasmodic relief with a bulk-forming laxative, useful for patients with IBS and constipation. The original branded preparations include Colofac and Colofac IBS, alongside several generic equivalents.
Mebeverine is targeted at the abdominal pain, cramping, and bloating components of IBS rather than at altered bowel habit, and is recommended by NICE as an option for symptomatic management of IBS in adults and young people aged 10 and over.
Mebeverine is a prescription-only medication in the UK at the 135 mg and 200 mg prescription strengths. (Lower-strength formulations may be available from a pharmacist for short-term symptomatic use without prescription.) A licensed clinician should confirm the diagnosis of IBS, exclude red-flag features, and review the patient's overall management plan before prescribing.
What Conditions Is Mebeverine Used For?
Mebeverine is prescribed for the symptomatic relief of:
Mebeverine is the most established antispasmodic recommended by NICE for the symptomatic relief of abdominal pain, cramping, bloating, and altered bowel habit associated with irritable bowel syndrome (IBS) in adults and young people aged 10 and over. It is effective across IBS subtypes — diarrhoea-predominant (IBS-D), constipation-predominant (IBS-C), and mixed-pattern (IBS-M) — because it targets the smooth-muscle hyperactivity that drives pain rather than acting on stool form.
Mebeverine is used for the symptomatic management of intestinal spasm, abdominal cramping, and discomfort arising from chronic functional bowel disorders including chronic irritable colon, spastic colitis, and mucous colitis. By relaxing colonic smooth muscle without interfering with normal peristalsis, it provides targeted relief from spasm-related pain without causing constipation.
Mebeverine may be prescribed to relieve abdominal cramping and spasm associated with diverticular disease of the colon, where smooth-muscle hyperactivity in affected colonic segments contributes to pain. It does not treat the underlying diverticular pathology or any complicating inflammation (diverticulitis), but provides symptomatic relief from spasm-driven pain in uncomplicated cases.
Mebeverine is used short term for the relief of abdominal cramping, pain, and discomfort arising from non-specific intestinal spasm — for example after gastrointestinal infection, dietary indiscretion, or stress-related functional gut symptoms. Where symptoms persist beyond two to four weeks, further clinical assessment is recommended to exclude underlying pathology.
Mebeverine treats the muscle spasm and abdominal pain associated with IBS and similar functional bowel disorders, but it does not address the underlying drivers of these conditions — such as dietary triggers, gut-microbiome changes, stress, and visceral hypersensitivity. Optimal IBS management combines antispasmodic treatment with dietary review (often including a structured low-FODMAP trial), stress management, regular physical activity, and, where appropriate, psychological therapies such as gut-directed cognitive behavioural therapy or hypnotherapy.
How Does Mebeverine Work?
Mebeverine is a musculotropic antispasmodic that acts directly on the smooth muscle of the gastrointestinal tract, with virtually no systemic anticholinergic activity. Its targeted action distinguishes it from older antispasmodics (such as hyoscine) and explains its favourable tolerability profile.
Direct smooth-muscle relaxation via sodium channel blockade: Mebeverine's principal mechanism is inhibition of voltage-gated sodium channels in the membrane of colonic smooth-muscle cells. The influx of sodium ions through these channels is the trigger that initiates muscle contraction. By reducing sodium entry, mebeverine decreases the excitability of the muscle cells, reducing the frequency and intensity of involuntary contractions that produce the cramping pain of IBS.
Modulation of calcium release and potassium efflux: Mebeverine also influences calcium release from intracellular stores and modulates potassium channels in colonic smooth muscle, further damping the contractile response. The combined effect is a reduction in pathological hypermotility without abolishing normal peristalsis — a critical distinction that allows mebeverine to relieve cramp without causing constipation.
Minimal anticholinergic and systemic effects: Unlike anticholinergic antispasmodics (such as hyoscine butylbromide), mebeverine has only weak antimuscarinic activity and negligible central nervous system penetration. This means it does not cause the typical anticholinergic side-effect profile (dry mouth, blurred vision, urinary retention, sedation) that limits the use of older antispasmodics. Mebeverine is metabolised rapidly to inactive metabolites and excreted in the urine, contributing to its low risk of accumulation and drug interaction.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Take mebeverine 20 minutes before meals, not with food. Pre-meal dosing allows the medication to be active during the post-meal period when gut contractions and IBS pain are typically at their strongest, which is when symptom relief is most valuable.
Swallow the tablets or capsules whole with a glass of water. Do not crush, chew, or break the modified-release 200 mg capsules — doing so disrupts the slow-release mechanism and can cause uneven absorption.
Take consistently every day for the best results. Mebeverine works best as regular preventative treatment rather than only when symptoms flare. Many patients notice meaningful improvement after 1–2 weeks of consistent use.
If using Fybogel Mebeverine (combined preparation with ispaghula husk), mix the sachet contents with a full glass of cool water, stir, and drink immediately. Follow with additional fluids during the day to prevent the fibre component from causing constipation or oesophageal obstruction.
Do not stop mebeverine abruptly after prolonged use — taper the dose gradually over one to two weeks if discontinuation is planned, to reduce the risk of symptom rebound.
Review treatment with your clinician after four weeks if symptoms have not improved, or sooner if symptoms worsen or new alarm features (weight loss, bleeding, persistent change in bowel habit) develop.
Side Effects of Mebeverine
Mebeverine is generally very well tolerated. Most patients experience no side effects at all. Serious side effects are rare but require immediate medical attention when they occur.
- Mebeverine is generally very well tolerated; reported side effects are uncommon
- Mild dizziness
- Headache
- Indigestion or mild nausea
- Loss of appetite
- Mild constipation (less common; usually reflects underlying IBS pattern rather than the medication itself)
- Allergic and hypersensitivity reactions — urticaria (hives), angioedema (swelling of the face, lips, tongue, or throat), and anaphylaxis have been reported, although they are rare; stop the medication and seek urgent medical attention
- Severe skin reactions — widespread rash, blistering, or peeling of the skin; rare but require immediate medical review
- Worsening or persistent abdominal symptoms — if abdominal pain, bloating, or altered bowel habit worsens significantly during treatment, or if new alarm features develop (weight loss, rectal bleeding, anaemia), arrange clinical reassessment promptly to exclude alternative diagnoses
Mebeverine has one of the most favourable safety profiles of any antispasmodic in clinical use. Side effects are uncommon, and when they occur are usually mild and self-limiting. This makes mebeverine a particularly suitable choice for long-term IBS management in patients who require sustained antispasmodic therapy or who are sensitive to the anticholinergic side effects of alternatives such as hyoscine. The most important safety consideration is not the side-effect profile of the drug itself but ensuring that the underlying diagnosis is correct — in particular, that red-flag features of more serious bowel pathology have been excluded before symptomatic treatment is started.
Drug Interactions
Mebeverine has a notably favourable drug-interaction profile and is one of the safer options for patients already taking multiple medications. Nevertheless, you should always disclose all prescription medications, over-the-counter medicines, vitamins, and supplements to your clinician or pharmacist before starting mebeverine.
Mebeverine has no clinically significant interaction with alcohol and is not known to affect alertness. However, alcohol is itself a recognised trigger for IBS symptoms in many patients, and excessive intake may worsen abdominal cramping, bloating, and altered bowel habit. Moderation is generally advisable while symptoms are active.
Mebeverine has minimal effect on the cytochrome P450 enzyme system and no clinically significant pharmacokinetic interactions have been documented with commonly co-prescribed medication. This makes it a useful antispasmodic option in patients on multiple long-term medications (for example, antihypertensives, statins, antidepressants) where interaction risk is otherwise a concern.
Combining mebeverine with other antispasmodic agents — such as hyoscine butylbromide (Buscopan), peppermint oil capsules, or alverine — is generally unnecessary and offers no clear additional benefit. Where multiple antispasmodic treatments are being considered, the clinician will usually trial each in turn rather than combining them.
Important Warnings
Abdominal pain is a non-specific symptom with many possible causes. Before starting mebeverine for presumed IBS, your clinician must exclude alarm features that suggest more serious pathology — including unintentional weight loss, rectal bleeding, persistent change in bowel habit in patients over 50, nocturnal symptoms, family history of bowel or ovarian cancer, anaemia, or abdominal masses. These features warrant urgent investigation rather than empirical antispasmodic treatment.
Mebeverine is contraindicated in patients with paralytic ileus (absence of bowel motility) — a condition in which further smooth-muscle relaxation could worsen abdominal distension and mask serious abdominal pathology. It is also contraindicated in patients with known hypersensitivity to mebeverine or to any of the excipients in the tablet or capsule formulation.
Although safety data in pregnancy are limited, mebeverine has not been associated with significant teratogenic risk in available reports. It is generally avoided in pregnancy as a precaution unless the clinical benefit clearly outweighs the theoretical risk. It is not known whether mebeverine passes into breast milk, so use during breastfeeding is generally avoided. Pregnant or breastfeeding patients should discuss safer alternatives with their clinician.
Rare hypersensitivity reactions to mebeverine have been reported, including urticaria, angioedema (swelling of the face, lips, tongue, or throat), and anaphylaxis. Stop the medication immediately and seek urgent medical attention if you develop difficulty breathing, facial swelling, widespread rash, or severe itching after taking mebeverine.
Mebeverine is not licensed for use in children under 10 years of age, as safety and efficacy in this age group have not been established. Abdominal pain in young children should always be assessed clinically to exclude organic causes before considering symptomatic treatment.
If your abdominal symptoms do not improve after four weeks of mebeverine treatment, or if they worsen at any point, contact your clinician for review. Lack of response may indicate that the underlying diagnosis needs to be re-examined, that an alternative treatment is required, or that further investigation is appropriate.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Mebeverine FAQs
Mebeverine typically begins to work within about an hour of taking a dose, with the antispasmodic effect lasting several hours. For best results, take it 20 minutes before meals so that it is active during the period of strongest gut activity (after eating), when IBS pain and cramping are usually most pronounced. Many patients notice meaningful symptom improvement within 1–2 weeks of regular use, though some respond more gradually.
The standard adult dose for the immediate-release tablets is 135 mg (one tablet) three times a day, taken 20 minutes before meals. The modified-release capsules are dosed as 200 mg twice daily, 20 minutes before breakfast and the evening meal. The combined preparation Fybogel Mebeverine (mebeverine plus ispaghula husk) is taken as one sachet twice daily before meals.
Mebeverine is generally considered safe for long-term use because it has no significant drug interactions, does not cause dependence, and has a very low rate of side effects compared with most other gut-acting medications. Many patients with chronic IBS take it for months or years. However, treatment should be periodically reviewed by your clinician — typically every 6–12 months — to confirm it is still needed and still effective.
Mebeverine and Buscopan (hyoscine butylbromide) are both antispasmodics used to relieve gut cramping, but they work in different ways. Mebeverine acts directly on the smooth-muscle cells of the gut by blocking sodium channels, with virtually no anticholinergic effect. Buscopan is an anticholinergic agent that blocks muscarinic receptors. As a result, mebeverine tends to be better tolerated and avoids the typical anticholinergic side effects (dry mouth, blurred vision, urinary hesitancy) seen with Buscopan, and is preferred for longer-term IBS management.
Yes — there is no clinically significant interaction between mebeverine and alcohol, and mebeverine does not affect alertness or your ability to drive. However, alcohol itself is a common trigger for IBS symptoms in many people and may worsen abdominal cramping, bloating, or altered bowel habit. Moderate intake is reasonable, but it is worth observing whether alcohol seems to flare your symptoms.
If you forget a dose, take it as soon as you remember unless it is nearly time for the next dose — in which case skip the missed dose and continue with your normal schedule. Do not take a double dose to make up for the missed one. Because mebeverine is taken to prevent post-meal spasm, an occasional missed dose is unlikely to cause harm, though regular adherence gives the best symptom control.
Mebeverine is generally avoided in pregnancy and breastfeeding as a precaution, although there is no strong evidence of harm. If treatment for IBS or intestinal cramping is needed during pregnancy or while breastfeeding, your clinician will discuss the available options and weigh the benefits against any theoretical risk. Do not start or continue mebeverine in pregnancy or breastfeeding without clinical advice.